MAPLIGHT THERAPEUTICS INC (MPLT) Fundamental Analysis & Valuation

NASDAQ:MPLT • US56565P1030

Current stock price

30.31 USD
-0.33 (-1.08%)
At close:
29 USD
-1.31 (-4.32%)
After Hours:

This MPLT fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. MPLT Profitability Analysis

1.1 Basic Checks

  • In the past year MPLT has reported negative net income.
  • MPLT had a negative operating cash flow in the past year.
MPLT Yearly Net Income VS EBIT VS OCF VS FCFMPLT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 2025 -50M -100M -150M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -154.27%, MPLT is doing worse than 85.44% of the companies in the same industry.
  • The Return On Equity of MPLT (-203.52%) is worse than 70.49% of its industry peers.
Industry RankSector Rank
ROA -154.27%
ROE -203.52%
ROIC N/A
ROA(3y)-50.4%
ROA(5y)N/A
ROE(3y)-60.22%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MPLT Yearly ROA, ROE, ROICMPLT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 2025 -50 -100

1.3 Margins

  • MPLT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MPLT Yearly Profit, Operating, Gross MarginsMPLT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. MPLT Health Analysis

2.1 Basic Checks

  • MPLT has more shares outstanding than it did 1 year ago.
  • There is no outstanding debt for MPLT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
MPLT Yearly Shares OutstandingMPLT Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 2025 10M 20M 30M 40M
MPLT Yearly Total Debt VS Total AssetsMPLT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 2025 100M 200M 300M 400M

2.2 Solvency

  • An Altman-Z score of 29.59 indicates that MPLT is not in any danger for bankruptcy at the moment.
  • MPLT's Altman-Z score of 29.59 is amongst the best of the industry. MPLT outperforms 91.65% of its industry peers.
  • There is no outstanding debt for MPLT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 29.59
ROIC/WACCN/A
WACCN/A
MPLT Yearly LT Debt VS Equity VS FCFMPLT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 2025 0 100M -100M 200M 300M 400M

2.3 Liquidity

  • MPLT has a Current Ratio of 4.89. This indicates that MPLT is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of MPLT (4.89) is comparable to the rest of the industry.
  • A Quick Ratio of 4.89 indicates that MPLT has no problem at all paying its short term obligations.
  • With a Quick ratio value of 4.89, MPLT perfoms like the industry average, outperforming 54.76% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.89
Quick Ratio 4.89
MPLT Yearly Current Assets VS Current LiabilitesMPLT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 2025 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. MPLT Growth Analysis

3.1 Past

  • The earnings per share for MPLT have decreased strongly by -891.36% in the last year.
EPS 1Y (TTM)-891.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-183.63%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 8.76% on average over the next years. This is quite good.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y44.25%
EPS Next 2Y20.01%
EPS Next 3Y11.11%
EPS Next 5Y8.76%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MPLT Yearly Revenue VS EstimatesMPLT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2029 2030 2031 2032 2033 200M 400M 600M 800M 1B
MPLT Yearly EPS VS EstimatesMPLT Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 4 -4 6 -6

More info and screens

Find the best growth stocksShow best growing peers

0

4. MPLT Valuation Analysis

4.1 Price/Earnings Ratio

  • MPLT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year MPLT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MPLT Price Earnings VS Forward Price EarningsMPLT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MPLT Per share dataMPLT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3 -4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.01%
EPS Next 3Y11.11%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MPLT Dividend Analysis

5.1 Amount

  • MPLT does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MPLT Fundamentals: All Metrics, Ratios and Statistics

MAPLIGHT THERAPEUTICS INC

NASDAQ:MPLT (4/28/2026, 5:20:01 PM)

After market: 29 -1.31 (-4.32%)

30.31

-0.33 (-1.08%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-26
Earnings (Next)06-02
Inst Owners51.28%
Inst Owner Change0.06%
Ins Owners3.56%
Ins Owner Change49.84%
Market Cap1.29B
Revenue(TTM)N/A
Net Income(TTM)-129.76M
Analysts87.27
Price Target33.32 (9.93%)
Short Float %8.54%
Short Ratio6.57
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)5.38%
PT rev (3m)5.38%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-6.87%
EPS NY rev (3m)-6.87%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 20.17
P/tB 20.17
EV/EBITDA N/A
EPS(TTM)-3.13
EYN/A
EPS(NY)-4.02
Fwd EYN/A
FCF(TTM)-2.39
FCFYN/A
OCF(TTM)-2.38
OCFYN/A
SpS0
BVpS1.5
TBVpS1.5
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -154.27%
ROE -203.52%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-50.4%
ROA(5y)N/A
ROE(3y)-60.22%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 79.94%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.89
Quick Ratio 4.89
Altman-Z 29.59
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)91.59%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-891.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-183.63%
EPS Next Y44.25%
EPS Next 2Y20.01%
EPS Next 3Y11.11%
EPS Next 5Y8.76%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-103.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-56.18%
EBIT Next 3Y-30.21%
EBIT Next 5Y-12.67%
FCF growth 1Y-74.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-75.27%
OCF growth 3YN/A
OCF growth 5YN/A

MAPLIGHT THERAPEUTICS INC / MPLT Fundamental Analysis FAQ

What is the fundamental rating for MPLT stock?

ChartMill assigns a fundamental rating of 2 / 10 to MPLT.


Can you provide the valuation status for MAPLIGHT THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to MAPLIGHT THERAPEUTICS INC (MPLT). This can be considered as Overvalued.


Can you provide the profitability details for MAPLIGHT THERAPEUTICS INC?

MAPLIGHT THERAPEUTICS INC (MPLT) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for MPLT stock?

The Earnings per Share (EPS) of MAPLIGHT THERAPEUTICS INC (MPLT) is expected to grow by 44.25% in the next year.